This is the bill as Congress filed it, with every figure linking back to the official record. Say how you\u2019d vote on it before the floor vote happens, and VoteWire will show you what your own representatives did. How it works →
Protecting Patient Access to Cancer and Complex Therapies Act
Latest action (Jul 7, 2025) — on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
What it does
not written yetThe Congressional Research Service writes the plain-English summary for every bill, usually a few weeks after it's introduced. This one doesn't have one yet. It will appear here when it does.
In the meantime the most reliable description is the bill's own official title, which is the heading above — written by its sponsor, and the only account of the bill that exists at this stage. The full text is on congress.gov ↗
We don't write our own summaries. Everything else on this site links back to a record you can check, and a description of a bill that came from us rather than from the bill would be the one thing here that didn't — on the page that asks you to take a position on it.
Face Value
as introducedHow much of this bill its name accounts for.
- Every bill starts at100
- Nothing counted against it: one area of law, and short enough that length doesn't register.
Face Value measures reach, not honesty. A big bill can be accurately named, and a low score is not an accusation — it means the contents reach further than any short title could describe. Count it yourself ↗ How this is worked out
Who lobbied on this
11 organizationsThese organizations told Congress, in their own quarterly disclosures, that they were lobbying on this bill.
- Abbvieno position stated
“S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act S. 2903, Safe Step Act H.R. 5509, Safe Step Act Drug cost and pricing policy…” filing ↗
- American College of Rheumatologyno position stated
“…Step Act (HR 5509/S. 668) Patient Access to Autoimmune Treatment, PAAT, Act (HR. 5467) Protecting Patient Access to Cancer and Complex Therapies Act (HR 4299) PBM Reform Act of 2025 (HR 4317) Workforce Mobility Act (S.2031) Specialty Physicians Advancing Rural Care, SPARC, Act (H.R 4681/S. 1380)…” filing ↗
- Amgen Inc.no position stated
“…Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations…” filing ↗
- Bristol-myers Squibb Companyno position stated
“H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act…” filing ↗
- Cencora, Inc.no position stated
“…Protecting Patient Access to Cancer and Complex Therapies Act 2025 (H.R.4299) Reimbursement policies impacting drug shortages Part B drug pricing changes Preventing and Mitigating Generic Drug Shortages CMS FY 2026…” filing ↗
- Genentech Inc.no position stated
“…H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies…” filing ↗
- Gilead Sciences, Inc.no position stated
“…Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation…” filing ↗
- Merck & Co., Inc.no position stated
“…Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.” filing ↗
- Pfizer Inc.no position stated
“…Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization…” filing ↗
- Pharmaceutical Research & Manufacturers of Americano position stated
“…- S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model S.3345 - PBM…” filing ↗
- Takeda Pharmaceuticals America, Inc.no position stated
“…Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.” filing ↗
Most filings say only that an organization lobbied on a bill, not which side it took — where that's the case we say so rather than guessing. Quotes are verbatim from the filing. How this is built.
Discussion
0 commentsSign in to join the discussion and put your vote on the record.
No comments yet. Be the first to make the case.